CTLA4 and neoplasm: However, breast cancer is a complex disease, with each molecular subtype exhibiting a heterogeneity of response to checkpoint blockade therapy, as well as varying PD-L1 and CTLA-4 expression, nonsynonymous tumor mutational burden, and expression of pro-inflammatory cytokines [54,55,56].